TapImmune Inc. (NASDAQ: TPIV) announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
The proposed transaction will be a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing. The proposed merger remains subject to certain conditions, including that financing and the approval of TapImmune stockholders.
Key Quote: “I believe that the new therapies we are acquiring with Marker in this transaction represent the next major leap forward in cell therapy for cancer. The merger adds to our product pipeline a synergistic portfolio of highly-differentiated T cell therapies that has demonstrated potentially groundbreaking results in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.” Peter Hoang, President and CEO of TapImmune
Disclosure
(TapImmune Inc. [NASDAQ: TPIV] is a client of RedChip Companies, Inc. TPIV agreed to pay RedChip Companies, Inc., a monthly cash fee of RedChip investor awareness services and consulting services)
154 words
Level Brands Inc. (NYSE American: LEVB) Hosted Conference Call to Discuss Second Quarter 2018 Results
Level Brands Inc. (NYSE American: LEVB), an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses, hosted a conference call on Wed., May 16, 2018, to discuss the company’s second quarter financial results and business progress.
What’s Next: Replay of May 16 conference call (available through May 30, 2018): domestic: 1-844-512-2921. International: 1-412-317-6671. Conference ID: 3680081
Disclosure
(Level Brands [NYSE: LEVB] is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for four months of RedChip investor awareness services.)
Canopy Growth (TSX: WEED) to List on NYSE
Canada’s biggest marijuana company, Canopy Growth (TSX: WEED), has applied to become the first cannabis producer to list on the New York Stock Exchange.
Why It Matters: Canopy Growth’s pending listing on the NYSE (expected before the end of May) adds further credibility to the soaring recreational and medical marijuana markets in the United States.
Key Quote: “Since becoming the first regulated cannabis producer to list their shares in North America in 2014, our team has focused on building credibility through consistent execution. Once finalized, listing our shares on the NYSE will represent a continuation of our upward trajectory as we build the global cannabis industry.” – Bruce Linton, Chairman & CEO
Crocs Inc. (NASDAQ: CROX) on Tuesday reported first-quarter net income of $16.5 million.
The Niwot, Colorado-based company said it had profit of 15 cents per share.
The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 11 cents per share.
The footwear company posted revenue of $283.1 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $271.9 million.
For the current quarter ending in July, Crocs said it expects revenue in the range of $315 million to $325 million. Analysts surveyed by Zacks had expected revenue of $310 million.
Crocs shares have risen 20 percent since the beginning of the year. The stock has more than doubled in the last 12 months.
The Backstory: Crocs, Inc. (NASDAQ: CROX) is a world leader in innovative casual footwear for women, men, and children, combining comfort and style with a value that consumers know and love. Every pair of shoes within Crocs’ collection contains Croslite™ material, a proprietary, molded footwear technology, delivering extraordinary comfort with each step.
178 words
U.S. Budget Deficit and Unemployment Rate Are Heading in Opposite Directions: Goldman Sachs Report
America’s budget deficit and unemployment rate are heading in opposite directions, and that has never happened before.
Goldman Sachs projects, for instance, that the 10-year treasury note could yield 6.6% next year to fund the deficit and will force the government to borrow more, which will push up interest rates.
The U.S unemployment rate is 3.9% and the budget deficit is expected to increase from $688 billion in 2017 to $1 trillion by 2020--a dual phenomenon that is highly uncommon in the U.S. (Goldman Sachs).
Small-cap stocks have been outpacing their larger rivals in recent months.
According to Ryan Vlastelica at Marketwatch, “There are a number of factors that have been supporting the category, including their getting a boost from the recently enacted tax overhaul, as well as strong earnings and revenue growth. In addition to these tailwinds, analysts say the small-cap group is benefiting from being insulated from the headwinds that are weighing on larger names.”
At its current levels, the Russell 2000 is just 1% below its record highs. The Dow and S&P 500 are closer to 6% off their record highs.
Green Spirit Industries (OTC: GSRX) completed construction on another of its five previously announced medicinal cannabis dispensary locations in Puerto Rico last week. Located in the Hato Rey district of San Juan, this dispensary will commence operations upon receipt of the requisite establishment license from the DHPR.
Why It Matters: Green Spirit has set aggressive growth targets in Puerto Rico and other markets in the United States. The completion of this latest dispensary in Puerto Rico further demonstrates the Company’s ability to execute on its plans. Additionally, due to limited licenses on the island, Green Spirit is setting itself apart from the competition with what could become a durable competitive advantage in the market.
What’s Next: In addition to its five planned dispensaries in Puerto Rico, one of which began generating sales in March, Green Spirit has staked out multiple opportunities in the massive California market, where it has invested and/or partnered in grow operations, manufacturing, and distribution. Led by former Macy’s Midwest Chairman, Les Ball, Green Spirit looks positioned for big success in 2018 and beyond.
Disclosure
(Green Spirit Industries [OTC: GSRX] is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services and 50,000 shares for investor awareness services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.)
Esports Entertainment (OTCQB: GMBL), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, signed an additional 10 epsorts teams to its affiliate marketing program last week. Combined with the previously announced affiliate deals, the Company now has 36 teams signed.
Key Quote: “No other esports wagering site has ever signed affiliate marketing agreement with esports teams, which serves as a testament to our P2P wagering model in which a player always wins, never the house.” – Grant Johnson, CEO
What’s Next: Esports Entertainment’s VIE.gg platform launched in the spring. Investors getting onboard now have a true ground-floor opportunity in an exciting space that could soar to tens of billions of dollars in the next few years.
Disclosure
(Esports Entertainment Group, Inc. [OTC:GMBL] is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.)
Nutriband (OTCQB: NTRB), a results-driven, health and pharmaceutical company focused on transdermal solutions, announced an exclusive 10-year deal with a leading Korean consumer products distributer, Best Choice Kim Nam-Hoon. Valued at $90 million, the deal will provide Best Choice exclusive distribution rights for Nutriband’s growing line of transdermal OTC health and wellness products in the Asia Pacific region, as long as order minimums and 10% year-over-year growth targets are met.
Why It Matters: The Best Choice deal provides a solid foundation of revenue growth for Nutriband as it works to bring its higher-value pharmaceutical line to market.
What’s Next: The market for health supplements is expected to reach $278 billion by 2024. Transdermal prescription products alone are expected to reach $120 billion by 2022. Nutriband is positioning itself as an early leader in this space, and we expect that developments in the near-term should further strengthen its leadership position.
Disclosure
(Nutriband Inc. [OTCQB:NTRB] is a client of RedChip Companies, Inc. NTRB agreed to pay RedChip Companies, Inc. 10,000 shares of Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.)
MamaMancini's Holdings, Inc. (OTCQB: MMMB), a marketer of specialty pre-prepared, frozen and refrigerated all-natural food products (as defined by the United States Department of Agriculture), on Tues., May 15, 2018 announced financial results for the fourth quarter and fiscal year 2018, ended Jan. 31, 2018.
The Backstory: Fiscal year 2018 revenue increased 53% to $27.5 million compared to fiscal 2017 revenue of $18.0 million. Net income available to common stockholders for fiscal year 2018 was $228,175 or $0.01 per diluted share, compared to a net loss of $506,001, or $(0.02) per diluted share, in fiscal 2017.
What It Means: The Company had a very solid year in fiscal 2018. MMMB is fleshing out its vision to develop new products that meet the needs of the rapidly growing sector of consumers that seek superior nutritional profiles, with all-natural ingredients and minimal prep time to serve their families. The Company will continue to employ this strategy to gain even more new customers around the country in fiscal 2019.
Key Quote: “We are pleased with the traction that we are continuing to achieve on our strategic business plan.” – Carl Wolf, Chief Executive Officer of MamaMancini's
What’s Next: The Company had a conference call Wednesday, May 16, 2018 to review the results of fiscal year 2018. A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10119588, through May 23, 2018.
Disclosure
(MamaMancini's Holdings, Inc. [OTCQB: MMMB] is a client of RedChip Companies, Inc. MMMB agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.)
236 words
Quote of the Week
"Invest in something you can get your arms around and be very conservative,
own enough stock so that you are not putting all your eggs in one basket."
- Dave Maley, Manager Ariel Discovery Fund
IDXG Fact Sheet: Interpace Diagnostics (NASDAQ: IDXG) is a fully integrated commercial organization that provides clinically useful molecular diagnostic tests and pathology services for evaluating the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. - March 2018
TPIV Fact Sheet: TapImmune (NASDAQ: TPIV) develops immunotherapies targeting tumors and metastatic diseases for a variety of cancers. The Company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer-vaccine approaches. - March 2018
IMRN Fact Sheet: Immuron Ltd (NASDAQ: IMRN) is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that can generate a wide range of products, all with a high safety profile. - March 2018
DGLY Fact Sheet: Digital Ally® (NASDAQ: DGLY) headquartered in Lenexa, Kan., specializes in the design and manufacture of the highest-quality video-recording equipment and video-analytic software. In industries such as law enforcement, emergency management, commercial fleets, and consumer use, Digital Ally pushes the boundaries of technology. - March 2018
CATS Fact Sheet: Catasys Inc. (NASDAQ: CATS) harnesses proprietary big-data predictive analytics, artificial intelligence, and telehealth. These elements, combined with human intervention and integrated, technology-enabled treatment solutions, deliver improved health to members and cost savings to health plans- March 2018
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
